About Daiichi Sankyo
Daiichi Sankyo is a company based in Tokyo (Japan) founded in 2005. The company has 19,770 employees as of March 31, 2024. Daiichi Sankyo has completed 3 acquisitions, including Ambit Biosciences, Luitpold and Plexxikon. Daiichi Sankyo operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, Merck, Roivant Sciences and BeiGene, among others.
- Headquarter Tokyo, Japan
- Employees 19770 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Daiichi Sankyo Company, Limited
-
Annual Revenue
$12.04 B (USD)17.77as on Mar 31, 2024
-
Net Profit
$1.88 B (USD)47.34as on Mar 31, 2024
-
EBITDA
$2.4 B (USD)50.82as on Mar 31, 2024
-
Latest Funding Round
$236.45 K (USD), Grant
Sep 10, 2021
- Investors
-
Employee Count
19770
as on Mar 31, 2024
-
Investments & Acquisitions
Ambit Biosciences
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Daiichi Sankyo
Daiichi Sankyo is a publicly listed company on the TSE with ticker symbol 4568 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Daiichi Sankyo
Unlock access to complete
Leadership Team
100 people
Software Development Team
38 people
Data Analysis and Operations Team
20 people
Product Management Team
17 people
Manager Team
16 people
Legal and Compliance
15 people
Sales and Marketing
13 people
Operations Team
9 people
Unlock access to complete
Funding Insights of Daiichi Sankyo
Investors in Daiichi Sankyo
Daiichi Sankyo has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include GrandEst.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Access and development services for government programs are provided.
|
Locked | Locked | Locked |
Investor details for Daiichi Sankyo
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Daiichi Sankyo
Daiichi Sankyo has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Ambit Biosciences, Luitpold and Plexxikon.
Investment portfolio details for Daiichi Sankyo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Kinase inhibitors for cancer and immune disorders were developed.
|
Locked | Locked | 2000 | Locked | |
|
Develops small molecule pharmaceuticals for oncology, CNS and autoimmune diseases
|
Locked | Locked | 2000 | Locked | |
|
Traditional pharma company engaged in development and marketing of variety of pharmaceutical products and medical devices
|
Locked | Locked | 1910 | Locked |
Complete acquisition details for Daiichi Sankyo
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Daiichi Sankyo
Detailed financials for Daiichi Sankyo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Daiichi Sankyo Comparisons
Peer comparison for Daiichi Sankyo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Daiichi Sankyo
Daiichi Sankyo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, Merck, Roivant Sciences and BeiGene, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
Detailed competitors of Daiichi Sankyo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Daiichi Sankyo
Complete news archive for Daiichi Sankyo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Daiichi Sankyo
Daiichi Sankyo was founded in 2005 and raised its 1st funding round 16 years after it was founded.
Daiichi Sankyo is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Sunao Manabe is the current CEO of Daiichi Sankyo.
As of Mar 31, 2024, the latest employee count at Daiichi Sankyo is 19,770.
Annual revenue of Daiichi Sankyo is $12.04B as on Mar 31, 2024.
The company was founded in 2005 and is headquartered in Tokyo, Japan. Operations center on the pharmaceutical sector, where drugs are developed for oncology, cardiovascular conditions, migraine, diabetes, and other therapeutic areas. Enhertu, a HER2-directed antibody-drug conjugate, is provided for breast cancer treatment. Additional products target various unmet medical requirements globally.
Daiichi Sankyo's top competitors include Merck, Moderna and Roivant Sciences.
Yes, Daiichi Sankyo is publicly traded on TSE under the ticker symbol 4568.
Daiichi Sankyo has made 3 acquisitions, including Ambit Biosciences, Luitpold, and Plexxikon.
Daiichi Sankyo has 1 investor. Key investors include GrandEst.
The ticker symbol of Daiichi Sankyo is 4568 on TSE.